178 related articles for article (PubMed ID: 37882947)
1. Pancreatic neuroendocrine tumor progression and resistance to everolimus: the crucial role of NF-kB and STAT3 interplay.
Vitali E; Valente G; Panzardi A; Laffi A; Zerbi A; Uccella S; Mazziotti G; Lania A
J Endocrinol Invest; 2024 May; 47(5):1101-1117. PubMed ID: 37882947
[TBL] [Abstract][Full Text] [Related]
2. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
[TBL] [Abstract][Full Text] [Related]
3. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
[TBL] [Abstract][Full Text] [Related]
4. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth.
De Simone V; Franzè E; Ronchetti G; Colantoni A; Fantini MC; Di Fusco D; Sica GS; Sileri P; MacDonald TT; Pallone F; Monteleone G; Stolfi C
Oncogene; 2015 Jul; 34(27):3493-503. PubMed ID: 25174402
[TBL] [Abstract][Full Text] [Related]
5. Cancer-Associated Fibroblasts Induce Proliferation and Therapeutic Resistance to Everolimus in Neuroendocrine Tumors through STAT3 Activation.
Amin T; Viol F; Krause J; Fahl M; Eggers C; Awwad F; Schmidt B; Benten D; Ungefroren H; Fraune C; Clauditz TS; Sauter G; Izbicki JR; Lohse AW; Huber S; Schrader J
Neuroendocrinology; 2023; 113(5):501-518. PubMed ID: 36473454
[TBL] [Abstract][Full Text] [Related]
6. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
[TBL] [Abstract][Full Text] [Related]
7. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer.
Gong J; Xie J; Bedolla R; Rivas P; Chakravarthy D; Freeman JW; Reddick R; Kopetz S; Peterson A; Wang H; Fischer SM; Kumar AP
Clin Cancer Res; 2014 Mar; 20(5):1259-73. PubMed ID: 24520096
[TBL] [Abstract][Full Text] [Related]
8. JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway.
Fang J; Chu L; Li C; Chen Y; Hu F; Zhang X; Zhao H; Liu Z; Xu Q
Oncol Rep; 2015 Jan; 33(1):494-502. PubMed ID: 25405520
[TBL] [Abstract][Full Text] [Related]
9. Targeting the mTOR signaling pathway in neuroendocrine tumors.
Chan J; Kulke M
Curr Treat Options Oncol; 2014 Sep; 15(3):365-79. PubMed ID: 25092520
[TBL] [Abstract][Full Text] [Related]
10. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
[TBL] [Abstract][Full Text] [Related]
11. Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors.
Cros J; Moati E; Raffenne J; Hentic O; Svrcek M; de Mestier L; Sbidian E; Guedj N; Bedossa P; Paradis V; Sauvanet A; Panis Y; Ruszniewski P; Couvelard A; Hammel P
Neuroendocrinology; 2016; 103(5):495-9. PubMed ID: 26335532
[TBL] [Abstract][Full Text] [Related]
12. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway.
Garner JM; Fan M; Yang CH; Du Z; Sims M; Davidoff AM; Pfeffer LM
J Biol Chem; 2013 Sep; 288(36):26167-26176. PubMed ID: 23902772
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.
Freitag H; Christen F; Lewens F; Grass I; Briest F; Iwaszkiewicz S; Siegmund B; Grabowski P
Neuroendocrinology; 2017; 105(1):90-104. PubMed ID: 27513674
[TBL] [Abstract][Full Text] [Related]
14. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
15. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Sims JT; Ganguly SS; Bennett H; Friend JW; Tepe J; Plattner R
PLoS One; 2013; 8(1):e55509. PubMed ID: 23383209
[TBL] [Abstract][Full Text] [Related]
16. Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells.
McFarland BC; Gray GK; Nozell SE; Hong SW; Benveniste EN
Mol Cancer Res; 2013 May; 11(5):494-505. PubMed ID: 23386688
[TBL] [Abstract][Full Text] [Related]
17. S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma.
Kaliyaperumal K; Sharma AK; McDonald DG; Dhindsa JS; Yount C; Singh AK; Won JS; Singh I
Redox Biol; 2015 Dec; 6():41-50. PubMed ID: 26177470
[TBL] [Abstract][Full Text] [Related]
18. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q
BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-kB and L1CAM activities.
Zuo C; Hong Y; Qiu X; Yang D; Liu N; Sheng X; Zhou K; Tang B; Xiong S; Ma M; Liu Z
Pancreatology; 2018 Apr; 18(3):328-333. PubMed ID: 29525378
[TBL] [Abstract][Full Text] [Related]
20. Wu Mei Wan attenuates CAC by regulating gut microbiota and the NF-kB/IL6-STAT3 signaling pathway.
Jiang F; Liu M; Wang H; Shi G; Chen B; Chen T; Yuan X; Zhu P; Zhou J; Wang Q; Chen Y
Biomed Pharmacother; 2020 May; 125():109982. PubMed ID: 32119646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
